文献速递核素与放射性配体治疗

肿瘤靶向白细胞介素2增强FAP导向放射性配体治疗的抗癌活性

Tumor-Targeted Interleukin 2 Boosts the Anticancer Activity of FAP-Directed Radioligand Therapeutics.
PubMed 文献 · J Nucl Med · 2023-12-01

在小鼠皮下HT-1080.hFAP和SK-RC-52.hFAP肿瘤模型中,研究177Lu标记的OncoFAP与BiOncoFAP联合L19-白细胞介素2的疗效。177Lu-BiOncoFAP的肿瘤自吸收剂量显著高于177Lu-OncoFAP,联合L19-IL2后所有注射小鼠均达完全缓解,蛋白组学提示自然杀伤细胞活化机制。

要点

  • 177Lu-BiOncoFAP在FAP阳性肿瘤的自吸收剂量显著高于177Lu-OncoFAP。
  • 单用L19-IL2或177Lu-BiOncoFAP仅少数动物获治愈。
  • 联合治疗在HT-1080.hFAP和SK-RC-52.hFAP模型均见全部完全缓解,提示协同。

核心结论

  • 基于OncoFAP的放射性配体治疗联合靶向白细胞介素2在FAP阳性肿瘤治疗中显示协同抗癌作用。
  • 作者指出该实验发现需未来临床研究证实。

研究设计与样本

  • 研究在荷皮下HT-1080.hFAP和SK-RC-52.hFAP肿瘤的小鼠中进行。
  • 通过SPECT/CT研究不同摩尔量(3 vs. 250 nmol/kg)注射配体时177Lu-OncoFAP和177Lu-BiOncoFAP的生物分布。
  • 评估5 MBq放射性制剂单用或联合L19-IL2的体内抗癌效果。
  • 对接受177Lu-BiOncoFAP、L19-IL2或两者联合治疗的动物肿瘤样本进行基于质谱的蛋白组学分析。

主要发现

  • 177Lu-BiOncoFAP在FAP阳性肿瘤的自吸收剂量为0.293 ± 0.123 Gy/MBq,显著高于177Lu-OncoFAP的0.157 ± 0.047 Gy/MBq(P = 0.01)。
  • 在高摩尔量注射配体时观察到有利的肿瘤-器官比值。
  • 单用L19-IL2或177Lu-BiOncoFAP仅使有限数量动物获癌症治愈。
  • 177Lu-BiOncoFAP联合L19-IL2治疗中,HT-1080.hFAP模型7/7完全缓解,SK-RC-52.hFAP模型4/4完全缓解。
  • 联合治疗后肿瘤微环境中颗粒酶和穿孔素1表达显著增强,机制涉及自然杀伤细胞活化。

关键数值与推荐

  • 177Lu-BiOncoFAP肿瘤自吸收剂量0.293 ± 0.123 Gy/MBq vs 177Lu-OncoFAP 0.157 ± 0.047 Gy/MBq(P = 0.01)。
  • 联合治疗完全缓解:HT-1080.hFAP模型7/7,SK-RC-52.hFAP模型4/4。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文结论指出该实验发现需未来临床研究证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We studied the antitumor efficacy of a combination of 177Lu-labeled radioligand therapeutics targeting the fibroblast activation protein (FAP) (OncoFAP and BiOncoFAP) with the antibody-cytokine fusion protein L19-interleukin 2 (L19-IL2) providing targeted delivery of interleukin 2 to tumors. Methods: The biodistribution of 177Lu-OncoFAP and 177Lu-BiOncoFAP at different molar amounts (3 vs. 250 nmol/kg) of injected ligand was studied via SPECT/CT in mice bearing subcutaneous HT-1080.hFAP tumors, and self-absorbed tumor and organ doses were calculated. The in vivo anticancer effect of 5 MBq of the radiolabeled preparations was evaluated as monotherapy or in combination with L19-IL2 in subcutaneously implanted HT-1080.hFAP and SK-RC-52.hFAP tumors. Tumor samples from animals treated with 177Lu-BiOncoFAP, L19-IL2, or both were analyzed by mass spectrometry-based proteomics to identify therapeutic signatures on cellular and stromal markers of cancer and on immunomodulatory targets. Results: 177Lu-BiOncoFAP led to a significantly higher self-absorbed dose in FAP-positive tumors (0.293 ± 0.123 Gy/MBq) than did 177Lu-OncoFAP (0.157 ± 0.047 Gy/MBq, P = 0.01) and demonstrated favorable tumor-to-organ ratios at high molar amounts of injected ligand. Administration of L19-IL2 or 177Lu-BiOncoFAP as single agents led to cancer cures in only a limited number of treated animals. In 177Lu-BiOncoFAP-plus-L19-IL2 combination therapy, complete remissions were observed in all injected mice (7/7 complete remissions for the HT-1080.hFAP model, and 4/4 complete remissions for the SK-RC-52.hFAP model), suggesting therapeutic synergy. Proteomic studies revealed a mechanism of action based on the activation of natural killer cells, with a significant enhancement of the expression of granzymes and perforin 1 in the tumor microenvironment after combination treatment. Conclusion: The combination of OncoFAP-based radioligand therapeutics with concurrent targeting of interleukin 2 shows synergistic anticancer effects in the treatment of FAP-positive tumors. This experimental finding should be corroborated by future clinical studies.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Galbiati A, Dorten P, Gilardoni E, et al. Tumor-Targeted Interleukin 2 Boosts the Anticancer Activity of FAP-Directed Radioligand Therapeutics. J Nucl Med. 2023. PMID: 37734838. doi:10.2967/jnumed.123.266007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。